Resof L Tablet

Resof L Tablet is a highly effective direct-acting antiviral (DAA) medication used for the treatment of chronic Hepatitis C Virus (HCV) infection. It is a fixed-dose combination containing Sofosbuvir 400 mg and Ledipasvir 90 mg, two clinically proven antiviral agents that work together to stop the replication of the Hepatitis C virus and eliminate it from the body. This advanced oral therapy has become one of the most trusted treatment options for chronic Hepatitis C because of its high cure rates, once-daily dosing, excellent tolerability, and interferon-free treatment regimen. Resof L Tablet provides patients with an effective solution that helps restore liver health while reducing the risk of long-term liver complications.

Resof L combines Sofosbuvir, an NS5B RNA polymerase inhibitor, with Ledipasvir, an NS5A inhibitor. Sofosbuvir works by blocking the viral RNA polymerase enzyme, preventing the Hepatitis C virus from producing new copies of itself. Ledipasvir inhibits the NS5A protein, which plays an essential role in viral replication and assembly. By targeting two different stages of the viral life cycle, this combination delivers a powerful antiviral effect that rapidly suppresses viral activity, minimizes the development of resistance, and significantly improves treatment success.

Resof L Tablet is primarily prescribed for adults with chronic Hepatitis C Genotypes 1, 4, 5, and 6. It is suitable for treatment-naïve patients as well as many individuals who have previously received antiviral therapy. Depending on the patient's viral genotype, liver condition, and medical history, healthcare professionals generally recommend a treatment duration of 12 weeks, while certain patients with advanced liver disease or compensated cirrhosis may require 24 weeks of therapy. Clinical studies have consistently reported sustained virologic response (SVR) rates of more than 95%, meaning that the Hepatitis C virus becomes undetectable after successful completion of treatment in the majority of patients.

The convenience of Resof L Tablet is one of its major advantages. The recommended dosage is one tablet taken orally once daily, with or without food, preferably at the same time every day. Taking the medication consistently helps maintain stable drug concentrations in the bloodstream, maximizing its antiviral effectiveness. Patients should complete the full prescribed treatment course without skipping doses or discontinuing therapy early, as doing so may reduce treatment success and increase the risk of viral recurrence.

Compared with traditional interferon-based therapies, Resof L offers a significantly improved safety profile and is generally well tolerated by most patients. Common side effects may include headache, fatigue, nausea, mild diarrhea, dizziness, weakness, and occasional insomnia. These side effects are typically mild and temporary, allowing patients to continue their daily routines throughout treatment. Serious adverse reactions are uncommon when the medication is taken under appropriate medical supervision. Healthcare providers may recommend routine blood tests and liver function monitoring during treatment to evaluate therapeutic response and ensure patient safety.

Before starting treatment, patients should inform their healthcare provider about any history of liver disease, kidney impairment, hepatitis B infection, HIV infection, pregnancy, breastfeeding, or any other significant medical conditions. It is also important to disclose all prescription medicines, over-the-counter medications, vitamins, and herbal supplements currently being used, as certain medications may interact with Sofosbuvir or Ledipasvir. Alcohol consumption should be avoided during treatment because it may further damage the liver and interfere with the healing process.

Successful treatment with Resof L Tablet not only eliminates the Hepatitis C virus but also helps prevent serious liver complications, including fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Achieving sustained virologic response significantly improves long-term liver function, reduces disease progression, and enhances the patient's overall quality of life. Early diagnosis and timely initiation of antiviral therapy remain essential for obtaining the best possible treatment outcomes.

Resof L Tablets should be stored in their original packaging in a cool, dry place away from excessive heat, direct sunlight, and moisture. The medicine should be kept out of the reach of children and should not be used after the printed expiration date. Proper storage helps preserve the medicine's stability, potency, and therapeutic effectiveness throughout its shelf life.

At Ayurmed Medicose, we are dedicated to supplying authentic, high-quality antiviral medicines that meet international pharmaceutical standards. We provide genuine Resof L Tablets sourced from trusted manufacturers, ensuring superior product quality, secure packaging, competitive pricing, and dependable worldwide delivery. Our commitment to product authenticity, ethical pharmaceutical distribution, and exceptional customer service has made Ayurmed Medicose a trusted supplier for hospitals, pharmacies, healthcare professionals, wholesalers, and international buyers. Through reliable pharmaceutical solutions and consistent quality assurance, we continue to support better Hepatitis C treatment outcomes and contribute to improved healthcare across global markets.